15 results
8-K
EX-99.1
FHTX
Foghorn Therapeutics Inc
8 Aug 23
Foghorn Therapeutics Announces Chief Medical Officer Succession
7:05am
experience and expertise in oncology and as a leukemia expert will be integral to our plans as we continue to advance our pipeline and develop medicines
8-K
EX-3.2
FHTX
Foghorn Therapeutics Inc
27 Oct 20
Amendments to Articles of Incorporation or Bylaws
5:00pm
such other person’s or entity’s professional or expert competence and that has been selected with reasonable care by or on behalf of the Corporation.
Section
S-1/A
EX-3.5
FHTX
Foghorn Therapeutics Inc
19 Oct 20
IPO registration (amended)
6:06am
are within such other person’s or entity’s professional or expert competence and that has been selected with reasonable care by or on behalf
S-1
EX-10.8
FHTX
Foghorn Therapeutics Inc
2 Oct 20
IPO registration
4:03pm
public accountant or by an appraiser or other expert selected with reasonable care by the Enterprise. In addition, the knowledge and/or actions
8-K
EX-99.2
FHTX
Foghorn Therapeutics Inc
4 Aug 23
Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update
7:05am
of Initial Onset: 4 to 42 days EXPERT ADJUDICATION COMMITTEE ASSESSMENT OF DIFFERENTIATION SYNDROME Potential DS Symptom include: Pleural effusion
8-K
EX-99.1
cc7yvztnja
8 Sep 23
Regulation FD Disclosure
7:04am
8-K
EX-99.1
6qtmnt 0rpg6
28 Jun 23
Regulation FD Disclosure
7:05am
8-K
EX-99.1
gxkgvcq
5 Jun 23
Regulation FD Disclosure
7:02am
DRS
mi5wsrjn
28 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next